A rapid antibody screening haemagglutination test for predicting immunity to sars-cov-2 variants of concern

HIGHLIGHTS

• who: Nina Urke Ertesvu00e5g from the pre-pandemic sera (n=128) were used as a negative control The mean endpoint titre was calculated for each sample. Samples with no detectable antibodies were assigned a titre of , for calculation purposes. Pseudotype-based neutralisation assay. The pseudotype-based neutralisation assay was performed in biosafety level , laboratory in Bergen, Norway. The SARS-Co, pseudotype virus was generated by co-transfection lentiviral vectors pHR`CMV-Luc, pCMVRu03948.2, and p, construct encoding the Wuhan or delta spike protein into HEK T cells as previously described23. The protease , and human , encoding constructs . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.